Iovance Biotherapeutics is trading 4.32% down at $8.07, with no clear company-specific negative catalyst emerging for August 26, 2026.
- Zacks highlighted Iovance among five biotech stock picks.
- TD Cowen raised its price target to $10 from $7 and maintained Buy.
- The biotech sector is up 2.06%; profit-taking after recent gains may explain the move, but remains unconfirmed.